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The optimal dose and duration of rabbit antithymocyte globulin (rATG) induction has not been defined. Methods. We compared
the safety and eﬃcacy of 2 dosing strategies, rATG 1.5 mg/kg for 4 days (n = 59) versus 2 mg/kg for 3 days (n = 59), in
a retrospective, cohort study. Results. Two-year rejection-free survival was 95% in each group (P = .983). Renal function
and infection rates were similar. The incidence of leucopenia was similar, although the 2 mg/kg group was more likely to be
thrombocytopenic on day 2 (4% versus 28%, P = .04). Length of stay tended to be longer for the 1.5 mg/kg group (6.0±3.7 versus
5.1 ± 1.9 days P = .104). A cost savings of $920 per patient for rATG were seen in the 2 mg/kg group (P = .122). Conclusions.
Shorter, more intense dosing of rATG is safe and eﬀective. The 3-day dose strategy resulted in a clinically shorter length of stay and
may result in cost savings.
1. Introduction
Induction therapy, using potent immunosuppressive agents
in the critical, early period of allograft placement with the
goal of decreasing the risk of acute rejection and potentially
allowing lower overall intensity of the maintenance immuno-
suppressive regimen, is common in kidney transplantation.
The induction agent of choice, along with dose and duration
is controversial, center-specific, and often based on limited
clinical data.
Rabbit antithymocyte globulin (rATG, Thymoglobulin,
Genzyme, Cambridge, MA) is FDA approved for treatment
of acute rejection at a dose of 1.5 mg/kg for 7–14 days based
on the results of a multicenter, double-blind randomized
trial [1, 2]. Although rATG is not currently FDA approved
as induction therapy in kidney transplantation, it is the most
commonly administered agent for this purpose. Over one-
half of the 70% of patients that receive an induction agent at
the time of kidney transplantation receive rATG. Induction
doses have ranged from 1–6 mg/kg/dose over 1–10 days with
a more typical regimen of 1.5 mg/kg for 3–5 days [3–11] with
a cumulative target of 4.5–10 mg/kg.
In animal models, higher initial doses of shorter duration
approximating a human-equivalent dose of 6 mg/kg were
associated with more peripheral and central lymphocyte
depletion and better allograft survival [12]. In humans,
total doses of 5.7 mg/kg on average given as 1.5 mg/kg per
day have been shown to produce similar outcomes in high
risk recipients who received an average of 10.3 mg/kg [9].
Based on these models the optimal induction dose is felt to
approximate 6 mg/kg [4, 7–10, 12].
Higher doses and prolonged duration of induction agents
are thought to be associated with an increased risk of
infection and the potential development of malignancy,
while low doses, <3 mg/kg, may not eﬀectively prevent acute
rejection [11]. Thus, the optimal dose and duration of rATG
have not been clearly defined. Therefore, the purpose of this
study was to evaluate the safety and eﬃcacy of two dosing
strategies of rATG, 1.5 mg/kg given for 4 days versus 2 mg/kg
given for 3 days.
2 Journal of Transplantation
2. Materials and Methods
This retrospective, single center, sequentially designed cohort
study evaluated adult renal transplant recipients receiving
rATG at Washington University/Barnes-Jewish Hospital.
Those transplanted between October 2005 and March 2006
who received 1.5 mg/kg of rATG for 4 days were compared to
those transplanted after April 2006 who received 2 mg/kg of
rATG for 3 days. The study was approved by the Washington
University Human Research Protection Oﬃce.
2.1. Patient Inclusion and Exclusion Criteria. All adult
renal transplant recipients were considered for enrollment.
Patients were excluded if their immunosuppression deviated
from protocol for the following reasons; those with a six–
antigen-matched living donor who do not receive induction
therapy at our institution, those with serologic evidence of
hepatitis B virus (HBV), hepatitis C virus (HCV), or multiple
organ transplant who may not receive full dose induction,
and patients enrolled in an investigational study.
2.2. Immunosuppression. Patients received quadruple
sequential immunosuppression consisting of induction with
rATG, followed by triple maintenance immunosuppression
with tacrolimus, azathioprine, or mycophenolic acid, and
prednisone.
The first dose of intravenous rATG was given over twelve
hours beginning before reperfusion. Subsequent doses were
given over six hours and withheld if the platelet count
dropped below 50,000 per mm3 or the white blood cell
(WBC) count dropped below 2,000 per mm3. If the platelet
count was between 50,000–75,000 per mm3 or the WBC
count was between 2,000–3,000 per mm3 the rATG dose was
halved. Patients in the 1.5 mg/kg group received 1.5 mg/kg
of rATG (based on total body weight with a maximum dose
150 mg per day) for 4 days and were compared to patients
that received 2 mg/kg (based on total body weight with a
maximum dose 200 mg per day) for 3 days. If a dose was held
for any reason it was not given the next day. Premedications
such as dipenydramine or acetaminophen were not routinely
given. Corticosteroids were administered daily.
Tacrolimus was initiated when patients achieved a brisk
diuresis (but no later than 3 days postoperatively) at a dose
of 0.1 mg/kg per day divided in two doses. Tacrolimus trough
levels were targeted at 5–10 ng/mL by microparticle enzyme
immunoassay (MEIA) (IMx, Abbott Laboratories, Abbott
Park, IL). Methylprednisolone was administered intraoper-
atively (7 mg/kg) to a maximum of 500 mg, followed by
prednisone 1 mg/kg/day to a maximum of 80 mg orally on
days in which rATG was administered and then tapered over
5 weeks to 5 mg/day. Mycophenolate mofetil at a dose of 500–
1000 mg or enteric coated mycophenolic acid sodium at a
dose of 360–720 mg was administered orally twice daily.
2.3. Antimicrobial Prophylaxis. Patients received nystatin
suspension for three months as fungal prophylaxis and
sulfamethoxazole/ trimethoprim double strength daily for
Pneumocystis jiroveci and bacterial prophylaxis. For patients
allergic to sulfa, dapsone 50 mg daily was substituted. For
viral prophylaxis, when either the donor or recipient had
serologic evidence of prior exposure to cytomegalovirus
(CMV), oral valganciclovir was given, 450 mg daily for 3–
12 months based on CMV risk status. Cytomegalovirus-
seronegative recipients of a CMV-seronegative donor
received acyclovir 200 mg orally twice daily for 3 months
posttransplant for Herpes simplex prophylaxis.
2.4. Outcomes and End Points. The primary endpoint of
this study was the rate of acute rejection. Secondary anal-
ysis included the time to and rate of serious infections,
patient survival, graft survival, acute rejection, incidence
of malignancy including posttransplant lymphoproliferative
disorder, complete blood counts, and renal function as
assessed by serum creatinine and estimated glomerular
filtration rate. Rabbit antithymocyte globulin drug costs were
estimated based on average wholesale price in 2009 [13].
2.5. Definitions. Serious infection was defined as an infection
prolonging the initial hospital stay or requiring hospital
admission. Cytomegalovirus infection and disease were
defined as previously described [14, 15]. Acute rejection
episodes were determined by the presence of clinical signs,
including a rise in serum creatinine and were confirmed in
all cases by biopsy as defined by the Banﬀ ’97 criteria [16].
Glomerular filtration rate was estimated by the abbreviated
modification of diet in renal disease (MDRD) formula [17].
Antibody results (ELISA or MHC class I or II antibodies) are
expressed as the number and percentage of patients with any
class I or II antibodies.
2.6. Database and Patient Followup. Patients at our center are
followed with a minimum of monthly labs and yearly clinic
visits. Patients are tracked at least yearly and their clinical
status is reported to UNOS. Our center uses an electronic
medical record system, Organ Transplant Tracking Record
(OTTR—HKS Medical Information Systems, Omaha, NE).
In addition, a research nurse monitors and records all
pertinent data from the medical records in a database for
research purposes.
2.7. Sample Size. The sample size was determined based on
an alpha of 0.05 and a power of 0.80, to find a 25% diﬀerence
in acute rejection. To achieve this at least 59 patients needed
to be analyzed in each group.
2.8. Statistics. Incidence of infection, acute rejection, graft
loss, and death were calculated using survival analysis tech-
niques. Univariate analysis was performed by the Student’s
t-test for continuous variables and the Chi-squared test for
categorical variables. All statistical tests were two-tailed and
a P value of <0.05 was considered significant.
3. Results
Between October 2005 and September 2006, 150 kidney
transplants were performed. Patients were excluded because
of multiple organ transplant (n = 7), positive HCV serology
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Table 1: Recipient and Donor Characteristics.
Recipient Characteristics 1.5 mg/kg x 4 days (n = 59) 2 mg/kg x 3 days (n = 59) P value
Age, yrs 52± 13 49± 13 .136
% of Patients >60 yrs, Number (%) 22 (37%) 16 (27%) .237
Race, Number (%) .490
White 46 (78%) 44 (75%)
Black 12 (20%) 11 (19%)
Gender, Number (%) .456
Female 23 (39%) 27 (46%)
Weight (kg) 84± 18 79± 21 .215
Body Mass Index (kg/m2) 28± 5 27± 7 .566
Transplant Type, Number (%) .353
Deceased Donor 31 (53%) 36 (61%) .559
Expanded Criteria Donor 9 (15%) 1 (2%) .008
Pretransplant Dialysis 43 (73%) 44 (75%) .834
Transplant Number, Number (%)
First 57 (97%) 58 (98%) .559
Cause of Renal Disease, Number (%) .572
Hypertension 22 (37%) 14 (24%)
Diabetes 10 (17%) 10 (17%)
Polycystic Kidney Disease 10 (17%) 9 (15%)
Glomerulonephritis 10 (13%) 14 (24%)
Lupus 1 (2%) 3 (5%)
Other 6 (10%) 9 (15%)
Donor Age 39± 14 37± 11 .412
CMV Serostatus Donor/Recipient, Number (%) .381
Negative/negative 8 (14%) 10 (17%)
Positive/negative 16 (27%) 9 (15%)
Negative/positive 17 (29%) 16 (27%)
Positive/positive 18 (31%) 24 (41%)
Class I antibody, Number (%) 6 (10%) 14 (24%) .050
Class II antibody, Number (%) 9 (15%) 7 (12%) .590
Cold Ischemia Time, (hrs) 11± 5 13± 6 .110
Delayed Graft Function, Number (%) 4 (7%) 5 (8%) .729
Mean ± SD.
Abbreviations: ESRD: end stage renal disease, CMV: cytomegalovirus.
(n = 1), no induction due to a six-antigen-matched live
donor (n = 2), and participation in an investigational study
(n = 22). The average time of followup was 2.3± 0.1 years in
the 1.5 mg/kg group and 1.9± 0.1 in the 2 mg/kg group.
3.1. Recipient and Donor Characteristics. There were no
diﬀerences in baseline recipient or donor characteristics
Table 1. Overall, the mean recipient age was 51 years with
approximately 1/3 of patients over the age of 60 years.
Eighteen percent of the patients were black. Most recipients
were male, not sensitized, and received a first deceased donor
allograft.
3.2. Rejection and Graft Function. At two-years after trans-
plantation rejection-free survival was 95% in both groups,
P = .983. At last followup, 3 patients in the 1.5 mg/kg
group and 3 patients in the 2 mg/kg group had suﬀered
an acute rejection Table 2. Grade I rejections were most
common in both groups, although one patient in the 2 mg/kg
group suﬀered a grade III rejection. Most of the rejections
occurred within the first year after transplantation, although
one 1.5 mg/kg patient suﬀered a late rejection at 540 days
after transplantation.
Serum creatinine was similar in the 1.5 mg/kg group
and the 2 mg/kg group at baseline (7.6 ± 3.3 mg/dL versus
8.4±3.6 mg/dL, P = 0.207), 6 months (1.4±0.4 mg/dL versus
1.3± 0.4 mg/dL, P = .383), 12 months after transplantation
(1.4 ± 0.5 mg/dL versus 1.4 ± 0.5 mg/dL, P = 0.748), and
at last followup (1.6 ± 1.3 mg/dL versus 1.6 ± 0.9 mg/dL,
P = .898). The estimated glomerular filtration rate [16] was
similar in the 1.5 mg/kg group and the 2 mg/kg group at
baseline (10± 5 mL/min versus 10± 7 mL/min, P = .766), 6
months (67± 29 mL/min versus 69± 22 mL/min, P = .646),
at 12 months after transplantation (68 ± 37 mL/min versus
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Table 2: Outcomes.
1.5 mg/kg × 4 days (n = 59) 2 mg/kg × 3 days (n = 59) P value
Patient Survival, #(%) 57 (97%) 59 (100%) .317
Graft Survival, #(%) 54 (92%) 56 (95%) .766
Freedom from Rejection, #(%) 56 (95%) 56 (95%) .983
Grade of Rejection, #(%)
Grade I 3 2
Grade II 0 0
Grade III 0 1
Infection #(%)∗ 7 (12%) 12 (20%) .142
Viral 2 3
Fungal 0 1
Bacterial 6 8
Site
Blood 5 5
Urine 1 1
Skin and Soft Tissue 1 3
Lung 0 1
Other/ Unknown 1 2
PTLD, #(%) 0 (0%) 0 (0%)
Tumor, #(%) 3 (5%) 1 (2%) .309
CMV Infection, #(%) 1 (2%) 2 (3%) .154
Length of Stay (days) 6.0± 3.7 5.1± 1.9 .104
Serum Creatinine (mg/dL)
Baseline 7.6± 3.3 8.4± 3.6 .207
6 months 1.4± 0.4 1.3± 0.4 .383
12 months 1.4± 0.5 1.4± 0.5 .748
Last followup 1.6± 1.3 1.6± 0.9 .898
GFR (mg/mL)
Baseline 10± 5 10± 7 .766
6 months 67± 29 69± 22 .646
12 months 68± 37 67± 23 .867
Last followup 65± 39 68± 23 .642
Total Dose (mg) 474± 132 450± 119 .308
rATG Doses (#) 3.7± 0.7 3.0± 0.5
Mean ± SD.
Abbreviations: PTLD, posttransplant lymphoproliferative disorder, CMV, cytomegalovirus, GFR, glomerular filtration rate.
∗One patient had a bacterial and viral infection.
67 ± 23 mL/min, P = .867), and last followup (65 ± 39
mL/min versus 68± 23 mL/min, P = .642).
3.3. Infection. The two-year incidence of serious infection
was similar between the groups, 12% in the 1.5 mg/kg group
and 20% in the 2 mg/kg group, P = 0.142 Figure 1. Eight
patients had infections in the 1.5 mg/kg group that consisted
of 6 bacterial infections and 2 viral infections Table 2.
Thirteen patients had infections in the 2 mg/kg group; 8 were
bacterial, 3 viral, and 1 fungal. There incidence of CMV
viremia was similar (1 (2%) in the 1.5 mg/kg group and 2
(3%) in the 2 mg/kg group). Blood was the most common
site for infection in both groups. There were no cases of BK
nephropathy during this time period.
3.4. Survival. Two-year patient survival was similar between
the groups, 97% in the 1.5 mg/kg group versus 100% in the
2 mg/kg group, P = .317. At last followup, two patients in
the 1.5 mg/kg group expired: a 67-year-old from myocardial
infarction at two years after transplantation and a 30-
year-old recipient of a kidney after lung transplant from
adenocarcinoma of unknown primary origin. All patients
were alive in the 2 mg/kg group. Two-year graft survival was
similar between the groups, 92% in the 1.5 mg/kg group
versus 95% in the 2 mg/kg group, P = .766. Five patients
lost their allograft in the 1.5 mg/kg group: 1 from early
thrombosis, 1 from early rejection, 1 at 403 days (a patient
who received an ECD kidney complicated by DGF, acute
rejection, CMV viremia, BK viremia, and listeria) and 2 died
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with a functioning graft. Three patients in the 2 mg/kg group
lost their allografts: 1 due to early rejection, 1 from metabolic
complications associated with a persistent eating disorder,
and 1 due to refractory plasmacytic rejection in a patient with
HCV.
3.5. Safety and Malignancy. White blood cell counts and
the percentage of patients with leucopenia were similar
in both groups throughout one-year after transplantation
Figures 2(a) and 2(b). The absolute lymphocyte count was
statistically lower in the 2 mg/kg arm on postoperative day
2, P = .042 Figure 2(c). The mean platelet counts were
similar throughout the study period, while the percentage of
patients with thrombocytopenia was higher in the 2 mg/kg
arm on postoperative day 2, (4%—1.5 mg/kg for 4 days
versus 28%—2 mg/kg for 3 days, P = .04) Figures 3(a) and
3(b). No patients received colony stimulating factors and
serum sickness did not occur.
Malignancy occurred in 3 patients in the 1.5 mg/kg group
(1 squamous cell cancer of the skin, 1 basal cell cancer of
the right temple, and 1 adenocarcinoma) and 1 patient in
the 2 mg/kg group (esophageal cancer). There were no cases
of posttransplant lymphoproliferative disorder. The average
length of stay for the transplant admission tended to be
longer in the 1.5 mg/kg for 4 days group compared to the
2 mg/kg for 3 days group (6.0±3.7 days versus 5.1±1.9 days,
P = .104).
3.6. Immunosuppression. The mean total dose of rATG in
the 1.5 mg/kg group was 474 ± 132 mg given over 3.7 ± 0.7
days (cumulative dose 5.7 ± 1.6 mg/kg) and the mean dose
of rATG in the 2 mg/kg group was 450 ± 119 mg given over
3.0 ± 0.5 days (cumulative dose 5.6 ± 1.3 mg/kg). Twelve
patients (20%) in the 1.5 mg/kg for 4 days arm did not
receive four doses of rATG (11 received fewer doses (19%)
and 1 received 5 doses). Nine patients (15%) in the 2 mg/kg
× 3 days arm did not receive 3 doses of rATG (6 received
fewer doses (10%) and 3 received 4 doses (5%)). The most
common reasons for a receiving fewer doses of rATG were
thrombocytopenia and leucopenia in both arms. In the
1.5 mg/kg for 4 days arm, 3 repeat transplant recipients
received only 2-3 doses of 1.5 mg/kg because of concerns over
excessive immunosuppression. One patient with prolonged
delayed graft function received an additional dose of rATG.
In the 2 mg/kg for 3 days arm, 3 patients received 4 doses of
1.5 mg/kg due to older age and debility.
3.7. Pharmacoeconomic. Average wholesale price (AWP) for
rATG was $ 610.00/ 25 mg vial [13]. The mean cost of
rATG in the 1.52 mg/kg group was $11, 569 ± 3, 239 and
in the 2 mg/kg group was $10, 649 ± 3, 178 (P = .122),
demonstrating a cost savings of $920.
4. Discussion
Studies conducted using rATG for induction have evaluated
the eﬃcacy and safety of a 7-day course of therapy dosed at
1.5 mg/kg/day [3] as well as a shorter, lower dose regimens
(3–6 mg/kg total dose) administered over 3 days [4, 7].
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Figure 1: Incidence of infection. The two-year incidence of
infection was similar between the groups, 12% in the 1.5 mg/kg
group and 20% in the 2 mg/kg group, P = .142.
Dosing regimens have ranged from total cumulative dose
of 3–10.5 mg/kg [2, 10]. Innovative dosing regimens have
been described, including one-time high dose administration
of 5 mg/kg [6, 10], intermittent dosing of rATG based on
CD3+ lymphocyte counts [5], and alternate day therapy
[7, 10]. Various timing, dosage and duration strategies
documented for rATG as induction therapy are summarized
in Table 3. Although allograft outcomes appear to be similar
among regimens, one trial demonstrated improved early
renal function (between postoperative days 1 through 4)
in renal transplant recipients that received a one time dose
rATG dose of 6 mg/kg versus 1.5 mg/kg every other day for 4
doses [10]. The authors speculated that rATG may induce a
dose-dependent reduction in reperfusion injury.
Cumulative doses of rATG less than 7.5 mg/kg appear to
be eﬀective in high risk renal transplant recipients [5, 8, 9].
Wong et al. published a recent, retrospective cohort study
that targeted rATG doses of 1.5 mg/kg given for 7–10 days.
Actual doses were significantly less than anticipated and
lower cumulative doses of rATG (less than 7.5 mg/kg) were as
safe and eﬀective as higher cumulative doses of rATG (greater
than 7.5 mg/kg). Acceptable rates of rejection and survival
were also demonstrated in a prospective, single group
trial of kidney and kidney-pancreas recipients that received
1.5 mg/kg of rATG doses based on CD3+ lymphocyte counts
(mean total cumulative dose 4.2 mg/kg) [7].
The present sequentially designed, retrospective cohort
study of 1.5 mg/kg of rATG for 4 days (n = 59) versus
2 mg/kg of rATG for 3 days (n = 59) demonstrates that
6 Journal of Transplantation
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Figure 2: Figures 2(a), 2(b), and 2(c). White blood cell counts and incidence of leucopenia. White blood cell counts and the percentage
of patients with leucopenia were similar in both groups throughout one year after transplantation. The absolute lymphocyte count was
statistically lower in the 2 mg/kg arm on postoperative day 2 (P = .42) but similar throughout the rest of the study period.
0
50
100
150
200
250
300
0 1 2 3 4 7 30 180 365
Days after transplantation
1.5 mg/kg ×4
2 mg/kg ×3
(a) Platelets × 1000/mm3
0
10
20
30
40
50
60
70
80
90
100
P = .04
Pe
rc
en
t
0 1 2 3 4 7 30 180 365
Days after transplantation
1.5 mg/kg ×4
2 mg/kg ×3
(b) Thrombocytopenia (<100,000/mm3)
Figure 3: Figures 3(a), and 3(b). The mean platelet counts were similar throughout the study period, while the percentage of patients with
thrombocytopenia was higher in the 2 mg/kg arm on postoperative day 2. At 2 days postoperatively, 4% of the 1.5 mg/kg group’s patients
had thrombocytopenia while 28% of the 2 mg/kg group had thrombocytopenia, P = .04.
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Table 3: Various rATG dosing regimens.
Author, Center Study Design Organ rATG Regimen Control
Brennan, Barnes-Jewish,
Wash U [3]
Prospective,
Randomized,
Double-blinded
K
1.5 mg/kg × 7days, total
10.5 mg/kg (n = 48)
Atgam 15 mg/kg ×
7d(n = 24)
Agha, Barnes-Jewish,
Wash U [4]
Prospective,
Nonrandomized
K
3.0 mg/kg/day, then
1.5 mg/kg × 2 days, total
6 mg/kg (n = 40)
1.5 mg/kg × 7d, total
10.5 mg/kg(n = 48)
Peddi, U of Cincinnati
[5]
Prospective,
Single-group
High risk K, KP
1.5 mg/kg, Intermittent
dosing, based on
CD3+monitoring, mean
total 4.2 mg/kg (n = 41)
Uncontrolled
Starzl, Pittsburg[6]
Prospective,
Single-group
K, P, L
∼5 mg/kg × 1 dose, total
5 mg/kg (n = 82) Uncontrolled
Stratta, Wake Forest [7]
Retrospective, Single
group
P
1.5 mg/kg, Alternate-day
therapy until calcineurin
inhibitor levels are
achieved, mean total
5.4 mg/kg (n = 55)
Uncontrolled
Wong, Massachusetts
General Hospital [8]
Prospective K
1.0 mg/kg × 3 day, total
3 mg/kg (n = 7)
1.5 mg/kg × 3 d, total
4.5 mg/kg (n = 9)
Gurk, U of Maryland [9] Retrospective cohort High risk K
Target 1.5 mg/kg ×
7-10day< 7.5 mg/kg
(n = 33)
>7.5 mg/ kg (n = 64)
Stevens, U of Nebraska
[10]
Prospective,
Randomized
K 6 mg/kg × 1 dose (n = 70) 1.5 mg/kg qod × 4 doses,
total dose 6 mg/kg (n = 72)
Abbreviations: K, kidney, P, pancreas, L, liver, KP, kidney pancreas.
both dosing strategies are equally eﬃcacious. Furthermore, a
higher daily dose (2 mg/kg with a maximum dose of 200 mg)
than the recommended (1.5 mg/kg with a maximum dose of
150 mg [1]) did not result in an increased risk of infection
or cancer and was associated with lower total mean dose of
rATG.
The benefits of a 2 mg/kg for 3-day dosing regimen
of rATG may include better use of healthcare resources
with opportunities for a lower dose and shorter length of
the initial transplant admission. In this study, the 2 mg/kg
group spent one less day in the hospital when compared
to the 1.5 mg/kg group. Larger studies powered to detect a
diﬀerence in hospital stay are needed to determine the full
impact of alternative dosing strategy on length of stay.
This study was performed as part of our ongoing quality
control measures to assess the impact of new regimens. The
major limitation of the study is that it was retrospectively
conducted. A study with larger patient numbers may be
necessary to demonstrate a diﬀerence in cost and length of
stay. Additionally, longer followup is warranted to fully study
the impact of rATG on malignancy. The external validity of
the study should also be considered. Most of the patients in
this study were Caucasian, first time transplant recipients,
and 43% of the recipients received live donor allografts.
Shorter, more intense dosing of rATG is safe and eﬀective.
This cohort study comparing rATG 1.5 mg/kg for 4 days
versus 2 mg/kg for 3 days demonstrates that both dosing
strategies are equally tolerated while allowing a low rate
of acute rejection. This alternate dosing strategy may allow
for shorter lengths of stay and lower mean doses, thus cost
savings.
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